Radiopharm Theranostics Limited (AU:RAD) has released an update.
Radiopharm Theranostics Limited, an Australian company specializing in radiopharmaceuticals, is aiming for a Nasdaq listing by the end of 2024. The listing, which will not raise additional capital, will be in the form of American Depositary Shares trading under the ticker RADX, complementing its ASX listing and aiming to enhance global investor access and liquidity. The company’s CEO expressed confidence that the Nasdaq listing will add value for all shareholders by broadening their investor base.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.
